OncoSec Medical Inc. (NASDAQ: ONCS)’s CEO, Punit Dhillon, recently published an opinion piece in which he discussed the progress being made in the field of immuno-oncology. He talked about how medical researchers have discovered that they can harness the power of the body’s immune system to combat cancer and other diseases. But what does Dhillon think about the future of OncoSec in cancer treatment industry?
According to Dhillon, OncoSec Medical Inc. (NASDAQ: ONCS) is coming in as a provider in an area of unmet medical need. While immunotherapies are being used to slowdown the progression of tumors or shrink them, there is still a major barrier that needs to be overcome. OncoSec’s medical technology is designed to help get over that barrier.
How OncoSec Medical Inc. (NASDAQ: ONCS) changes the game
There are numerous cases where immunotherapies have been used to identify and fight cancer cells with incredible success. However, the vast majority of patients are still not responding well to anti-PD-1 therapies. The problem of lack of response to DNA-based cancer therapies has been noted in patients short of tumor-infiltrating lymphocytes (TILs) in their systems.
Cancer suffers who have shortage of TILs are called non-responders and there are more than 1 million of them with solid tumors in the U.S. alone. In cases where there is a shortage of TILs, something must be done to facilitate the delivery and uptake of anti-PD-1 therapies. That is where OncoSec Medical Inc. (NASDAQ: ONCS) comes in with a product called ImmunoPulse IL-12.
What does IL-12 do?
OncoSec Medical Inc. (NASDAQ: ONCS)’s ImmunoPulse IL-12 has been through trials and turned up positive results, boosting hope that more cancer suffers could find help with immunotherapies to cope with their conditions. Tests have shown that ImmunoPulse IL-12 is capable of driving TILs into the tumor and after that it stimulates anti-cancer immune activities in the body.
According OncoSec Medical Inc. (NASDAQ: ONCS), the outcome of IL-12 trials has surpassed expectations. Therefore, the management is upbeat that the technology will be part of standard treatment for cancer using immune-oncology medicines.